Solventum’s $4.1 Billion Sale of Purification and Filtration Business to Thermo Fisher

Cleary Gottlieb advised Solventum in the definitive agreement to sell its purification and filtration business to Thermo Fisher Scientific Inc. (Thermo Fisher) for $4.1 billion.

Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, subject to regulatory approval and customary closing conditions.

Morgan Stanley & Co. LLC, Perella Weinberg Partners, and J.P. Morgan Securities LLC served as financial advisors to Solventum.

For more information, please see the press release.

Solventum pioneers game-changing innovations at the intersection of health, material, and data science that change patients’ lives for the better, while empowering healthcare professionals to perform at their best. Solventum was spun-off from long-time Cleary client 3M in 2024.

Thermo Fisher is the world leader in serving science, with annual revenue over $40 billion.